

What is Host-Directed Therapy in Pneumonia?



Youjin Chang

Organization The Catholic University of Korea, Seoul St. Mary's Hospital, Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine

Current Position Clinical Associate Professor

Educational background

2012-2020 Ph.D., University of Ulsan College of Medicine, Republic of Korea, Department of Pulmonary and Critical Care Medicine
2009-2012 M.Sc., University of Ulsan College of Medicine, Republic of Korea, Department of Pulmonary and Critical Care Medicine
2000-2006 M.D., Inje University, College of Medicine, Republic of Korea

Professional experience

2025 Clinical Associate Professor, The Catholic University of Korea, Seoul St. Mary's Hospital, Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine
2017-2025 Associate Professor, Assistant Professor, College of Medicine Inje University Sanggye Paik Hospital, Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine
2014-2017 Clinical Assistant Professor, Clinical Professor, Chungbuk National University Hospital, Korea, Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine
2013-2014 Clinical Instructor, University of Ulsan College of Medicine, Republic of Korea, Asan Medical Center, Department of Pulmonary and Critical Care Medicine
2011-2013 Clinical Fellow, University of Ulsan College of Medicine, Republic of Korea, Asan Medical Center, Department of Pulmonary and Critical Care Medicine

In pneumonia, the appropriateness of antibiotic therapy has not always been the decisive factor in patient outcomes. This indicates that prognosis may depend less on the pathogen itself and more on how the host responds to infection. The COVID-19 pandemic has highlighted the importance of host-directed therapies, and experiences from both influenza and COVID-19 have shown that the benefit of immune-modulating treatments can differ depending on their effects on the host immune system.

Host-directed therapies are defined as strategies that modulate host immunity against microbial pathogens. These can enhance immunity by strengthening host responses, such as with cytokine-modulating therapies, infusion of anti-pathogen antibodies in COVID-19, or vaccination. Alternatively, they may mitigate immunopathology by minimizing tissue injury caused by dysregulated immune responses, for example through anti-cytokine antibodies like IL-6 receptor blockers, cytokine modulators such as JAK inhibitors, complement inhibitors, and anti-inflammatory drugs, many of which were employed in severe COVID-19.

A central challenge, as seen in COVID-19, is determining the optimal timing for initiating and discontinuing therapy. To be effective, interventions must be delivered at the appropriate phase of the immune response: too early or too late may reduce benefit or even impair recovery. Clinical evidence has shown that once pneumonia advances beyond a certain stage, host-directed therapies may lose their effectiveness. This underscores the need for well-timed intervention that supports, rather than hinders, immune recovery. The contrasting outcomes of corticosteroid use in influenza versus COVID-19 further illustrate the importance of pathogen-specific differences in host immunity.

A deeper understanding of host-directed therapies offers a promising path forward. Independent of the growing challenge of antibiotic resistance, these approaches target the underlying host-pathogen interaction and hold potential to transform future strategies for the treatment of pneumonia.